Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
1997 2
1999 1
2000 2
2001 2
2003 1
2004 1
2005 1
2006 4
2007 1
2009 3
2010 2
2011 1
2012 2
2013 5
2015 2
2016 1
2018 1
2019 1
2020 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hormone-resistant breast carcinoma"
Page 1
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. Toy W, et al. Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. Nat Genet. 2013. PMID: 24185512 Free PMC article.
Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition. ...We conducted a comprehensive genetic analysis of two independent cohorts of metastatic ER-positive breast tumors and identified mutations in ESR1 a …
Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition. ...We conducted a …
Single cell profiling of female breast fibroadenoma reveals distinct epithelial cell compositions and therapeutic targets.
Chen Z, Zhang Y, Li W, Gao C, Huang F, Cheng L, Jin M, Xu X, Huang J. Chen Z, et al. Nat Commun. 2023 Jun 16;14(1):3469. doi: 10.1038/s41467-023-39059-3. Nat Commun. 2023. PMID: 37328469 Free PMC article.
Interestingly, epithelial cells exhibit hormone-responsive functional signatures and synchronous activation of estrogen-sensitive and hormone-resistant mechanisms (ERBB2, BCL2 and CCND1 pathways). We develop a human expandable FA organoid system and observe that mos …
Interestingly, epithelial cells exhibit hormone-responsive functional signatures and synchronous activation of estrogen-sensitive and hor …
Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.
Militaru FC, Militaru V, Crisan N, Bocsan IC, Udrea AA, Catana A, Kutasi E, Militaru MS. Militaru FC, et al. Biomol Biomed. 2023 Sep 4;23(5):760-771. doi: 10.17305/bb.2023.8782. Biomol Biomed. 2023. PMID: 37021836 Free PMC article. Review.
The most common genetic syndromes associated with prostate cancer risk are BRCA-associated hereditary breast and ovarian cancer (HBOC) and Lynch syndrome. Local-regional therapy, i.e., surgery is beneficial in early-stage prostate cancer management. ...Androgen receptor sp …
The most common genetic syndromes associated with prostate cancer risk are BRCA-associated hereditary breast and ovarian cancer (HBOC …
Cholesterol biogenesis is a PTEN-dependent actionable node for the treatment of endocrine therapy-refractory cancers.
Kaysudu I, Gungul TB, Atici S, Yilmaz S, Bayram E, Guven G, Cizmecioglu NT, Sahin O, Yesiloz G, Haznedaroglu BZ, Cizmecioglu O. Kaysudu I, et al. Cancer Sci. 2023 Nov;114(11):4365-4375. doi: 10.1111/cas.15960. Epub 2023 Sep 14. Cancer Sci. 2023. PMID: 37706278 Free PMC article.
PTEN and PIK3CA mutations are the most prevalent PI3K pathway alterations in prostate, breast, colorectal, and endometrial cancers. p110beta becomes the prominent PI3K isoform upon PTEN loss. ...According to our data, targeting cholesterol biosynthesis in combination with …
PTEN and PIK3CA mutations are the most prevalent PI3K pathway alterations in prostate, breast, colorectal, and endometrial cancers. p …
Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages.
Gelsomino L, Giordano C, Camera G, Sisci D, Marsico S, Campana A, Tarallo R, Rinaldi A, Fuqua S, Leggio A, Grande F, Bonofiglio D, Andò S, Barone I, Catalano S. Gelsomino L, et al. Biomolecules. 2020 Apr 3;10(4):543. doi: 10.3390/biom10040543. Biomolecules. 2020. PMID: 32260113 Free PMC article.
Obesity represents a risk factor for breast cancer development and therapy resistance, but the molecular players underling these links are unclear. ...In conclusion, acquired AI resistance is accompanied by the development of a leptin-driven phenotype, highlighting the pot …
Obesity represents a risk factor for breast cancer development and therapy resistance, but the molecular players underling these link …
Chemotherapy of breast cancer: a historical perspective.
Hortobagyi GN. Hortobagyi GN. Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-1-S17-4. Semin Oncol. 1997. PMID: 9374083 Review.
Over the last 30 years, our knowledge about the clinical behavior of breast cancer has increased substantially. Our ability to identify several prognostic subgroups and predict hormone-responsive and hormone-resistant disease has led to more rational utilizat …
Over the last 30 years, our knowledge about the clinical behavior of breast cancer has increased substantially. Our ability to identi …
Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer.
Saji S, Kimura-Tsuchiya R. Saji S, et al. Int J Clin Oncol. 2015 Apr;20(2):268-72. doi: 10.1007/s10147-015-0799-2. Epub 2015 Feb 24. Int J Clin Oncol. 2015. PMID: 25708592 Review.
Overcoming resistance to endocrine therapy is the most intensive research area in estrogen receptor (ER)-positive breast cancer. A strategy to restore endocrine sensitivity using molecular-targeted drugs such as mammalian target of rapamycin inhibitor everolimus along with …
Overcoming resistance to endocrine therapy is the most intensive research area in estrogen receptor (ER)-positive breast cancer. A st …
Biology of female sex hormone action in relation to contraceptive agents and neoplasia.
King RJ. King RJ. Contraception. 1991 Jun;43(6):527-42. doi: 10.1016/0010-7824(91)90002-w. Contraception. 1991. PMID: 1651204 Review.
Estrogens increase cell replication in endometrium, and progestins counter it. Breast cancer evolves in several cell types in the epithelium of the terminal ductal lobular unit, with a 20-year latency. ...The effect of steroids on the cervix is unclear, since cervical canc …
Estrogens increase cell replication in endometrium, and progestins counter it. Breast cancer evolves in several cell types in the epi …
Natural interferon-alpha activity in hormone-sensitive, hormone-resistant and autonomous human breast-cancer cell lines.
Iacopino F, Robustelli della Cuna G, Sica G. Iacopino F, et al. Int J Cancer. 1997 Jun 11;71(6):1103-8. doi: 10.1002/(sici)1097-0215(19970611)71:6<1103::aid-ijc29>3.0.co;2-c. Int J Cancer. 1997. PMID: 9185717
This study explored the activity of natural interferon-alpha (nIFN-alpha) in regulating cell growth of 6 breast-cancer cell lines. The anti-proliferative effect of the combination nIFN-alpha and tamoxifen (TAM) or medroxyprogesterone acetate (MPA) in CG-5 estrogen-sensitiv …
This study explored the activity of natural interferon-alpha (nIFN-alpha) in regulating cell growth of 6 breast-cancer cell lines. Th …
Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer.
Lee J, Jeong JH, Jung JH, Kim WW, Lee SJ, Park JY, Park JY, Kang SH, Kim EA, Park JH, Chae YS, Park HY. Lee J, et al. Oncology. 2019;97(3):180-188. doi: 10.1159/000501340. Epub 2019 Jul 22. Oncology. 2019. PMID: 31330520
BACKGROUND: Hormone receptor-positive breast cancer accounts for nearly two-thirds of breast cancer cases; it ultimately acquires resistance during endocrine treatment and becomes more aggressive. ...Thus, therapeutic strategies that target Del-1 may be effective fo …
BACKGROUND: Hormone receptor-positive breast cancer accounts for nearly two-thirds of breast cancer cases; it ultimately acqui …
38 results